7-6004056-G-C
Variant summary
Our verdict is Benign. The variant received -10 ACMG points: 2P and 12B. PM5BP4_StrongBP6_Very_Strong
The NM_000535.7(PMS2):c.166C>G(p.Leu56Val) variant causes a missense, splice region change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000321 in 1,527,534 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 17/22 in silico tools predict a benign outcome for this variant. 1/1 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Likely benign (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. L56P) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000535.7 missense, splice_region
Scores
Clinical Significance
Conservation
Publications
- Lynch syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet
- Lynch syndrome 4Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), Genomics England PanelApp
- mismatch repair cancer syndrome 1Inheritance: AR Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet
- mismatch repair cancer syndrome 4Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae)
- malignant pancreatic neoplasmInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- ovarian cancerInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- Muir-Torre syndromeInheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
- rhabdomyosarcomaInheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
- breast cancerInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
- prostate cancerInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
- hereditary breast carcinomaInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Benign. The variant received -10 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000535.7. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| PMS2 | NM_000535.7 | MANE Select | c.166C>G | p.Leu56Val | missense splice_region | Exon 3 of 15 | NP_000526.2 | ||
| PMS2 | NM_001406875.1 | c.-319C>G | 5_prime_UTR_premature_start_codon_gain | Exon 3 of 15 | NP_001393804.1 | ||||
| PMS2 | NM_001406876.1 | c.-50C>G | 5_prime_UTR_premature_start_codon_gain | Exon 3 of 14 | NP_001393805.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| PMS2 | ENST00000265849.12 | TSL:1 MANE Select | c.166C>G | p.Leu56Val | missense splice_region | Exon 3 of 15 | ENSP00000265849.7 | ||
| PMS2 | ENST00000382321.5 | TSL:1 | c.166C>G | p.Leu56Val | missense splice_region | Exon 3 of 11 | ENSP00000371758.4 | ||
| PMS2 | ENST00000406569.8 | TSL:1 | n.166C>G | splice_region non_coding_transcript_exon | Exon 3 of 13 | ENSP00000514464.1 |
Frequencies
GnomAD3 genomes AF: 0.0000460 AC: 7AN: 152044Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000483 AC: 12AN: 248552 AF XY: 0.0000223 show subpopulations
GnomAD4 exome AF: 0.0000305 AC: 42AN: 1375490Hom.: 0 Cov.: 23 AF XY: 0.0000232 AC XY: 16AN XY: 688994 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000460 AC: 7AN: 152044Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74266 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Benign:4
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
The missense variant NM_001322014.2(PMS2):c.166C>G (p.Leu56Val) has been reported to ClinVar as Benign/Likely benign with a status of (2 stars) criteria provided, multiple submitters, no conflicts (Variation ID 127765 as of 2025-08-07). There is a small physicochemical difference between leucine and valine, which is not likely to impact secondary protein structure as these residues share similar properties. The p.Leu56Val variant is not predicted to disrupt the existing acceptor splice site 3bp upstream by any splice site algorithm. The p.Leu56Val missense variant is predicted to be tolerated by both SIFT or PolyPhen2. For these reasons, this variant has been classified as Likely Benign.
Lynch syndrome 4 Benign:3
This variant is considered likely benign. Homozygosity for this variant has been confirmed in one or more individuals lacking clinical features consistent with gene-specific recessive disease, indicating that this variant is unlikely to be pathogenic.
not specified Benign:2Other:1
Variant summary: PMS2 c.166C>G (p.Leu56Val) results in a conservative amino acid change located in the DNA mismatch repair protein family, N-terminal domain (IPR002099) of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. Consensus agreement among computation tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 3.3e-05 in 1528896 control chromosomes, predominantly at a frequency of 0.00042 within the East Asian subpopulation in the gnomAD database. The observed variant frequency within East Asian control individuals in the gnomAD database is approximately 5.9 fold of the estimated maximal expected allele frequency for a pathogenic variant in PMS2 causing Hereditary Nonpolyposis Colorectal Cancer/Lynch Syndrome phenotype (7.1e-05), strongly suggesting that the variant is a benign polymorphism found primarily in populations of East Asian origin. c.166C>G has been reported in the literature in individuals who had a personal- and/or family history of colorectal cancer (Jiang_2019, Li_2019, Jiang_2020) or other tumor or cancer phenotypes (e.g. Mu_2016, Maxwell_2014, Pannuti_2018, Chan_2018, Wu_2021), but was also found in healthy controls (Bodian_2014). These report(s) do not provide unequivocal conclusions about association of the variant with Hereditary Nonpolyposis Colorectal Cancer/Lynch Syndrome. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 24728327, 30093976, 32914570, 30521064, 30166348, 31391288, 25503501, 27720647, 29570743, 34350294). ClinVar contains an entry for this variant (Variation ID: 127765). Based on the evidence outlined above, the variant was classified as benign.
not provided Benign:2
This variant is associated with the following publications: (PMID: 25503501, 24728327, 27720647, 30521064)
PMS2-related disorder Benign:1
This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications).
Ovarian cancer Benign:1
Hereditary nonpolyposis colorectal neoplasms Benign:1
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at